Dr Reddy’s Labs’ shares gained a little over 3 percent in the opening minutes as investors cheered a regulatory approval to its Drug.
The company announced an approval from US FDA and is launching Buprenorphine and Naloxone Sublingual Film, a therapeutic equivalent generic version of Suboxone
Buprenorphine and naloxone are used to treat adults with opioid addiction.
The stock has gained 16 percent in the past one month, while in the past three days, it has surged 6 percent. At 09:29 hrs Dr Reddys Laboratories was quoting at Rs 2,329.05, up Rs 60.65, or 2.67 percent, on the BSE. It touched an intraday high of Rs 2,345.95 and an intraday low of Rs 2,290.00.
Want to earn some profit click here
This post first appeared on After Italy Verdict Gold Trades Higher On Safe-haven Demands; Silver Down, please read the originial post: here